{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_5836", "batch_size": 200, "batch_pos": 82, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain any high-potency verbs, potent metaphors, critical alert phrases, superlatives + harm nouns, or intensifiers + harm nouns.", "method": "llm_batch", "batch_id": "batch_2_20000", "batch_size": 200, "batch_pos": 51, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the specified list paired with scale/impact information.", "method": "llm_batch", "batch_id": "batch_3_17784", "batch_size": 200, "batch_pos": 199, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
